Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...
Phase III program in food allergy (FA) planned for H2 2026 ...
CSU affects nearly 4 million people in Europe, with over 50% of patients remaining symptomatic despite H1-antihistamines2-4 ...
You can break new ground in how we bring treatments to patients when you join us in Sales. Collaborating closely with Marketing, Access and Medical teams, you’ll educate healthcare professionals about ...
Bryan Laffitte has had a long career at Novartis in San Diego, California—with some twists and turns. After spending thirteen years at Novartis in a variety of roles, he explored opportunities in ...
Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Εξερευνήστε ευκαιρίες στη Novartis παρακάτω. (高级）医药代表 /（资深）产品专员 Regular (Sales), Full time Sales China ...
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-controlled ...
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results